Santa Cruz Biotechnology supplies a comprehensive collection of CWC22 monoclonal antibodies for research focused on understanding CWC22's cellular functions. CWC22 monoclonal antibodies are validated for multiple applications, including western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry with paraffin-embedded sections (IHCP), flow cytometry (FCM), and enzyme-linked immunosorbent assay (ELISA). CWC22 is a crucial component of the spliceosome, playing a significant role in pre-mRNA splicing and the regulation of gene expression. The function of CWC22 is vital for maintaining proper cellular processes and ensuring the accurate processing of RNA transcripts. Dysregulation of CWC22 has been implicated in various diseases, making it a significant target for scientific investigation. Research has shown that CWC22 interacts with multiple splicing factors and regulatory proteins, highlighting its importance in RNA processing pathways. Understanding CWC22's molecular mechanisms can provide valuable insights into disease development and potential therapeutic strategies. Recent studies have revealed new aspects of CWC22's involvement in cellular signaling networks and disease progression. Santa Cruz Biotechnology monoclonal antibodies enable researchers worldwide to advance scientific understanding of CWC22's role in human health and disease.